Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401855 | 0.87 | TAAR1 (0.61) | TAAR1MAOB | |
| SCHEMBL874149 | 0.87 | TAAR1 (0.48) | TAAR1MAOB | |
| SCHEMBL15143758 | 0.83 | MAOB (0.58) | TAAR1MAOB | |
| SCHEMBL6568884 | 0.82 | TAAR1 (0.62) | TAAR1MAOB | |
| SCHEMBL2128463 | 0.82 | ALDH1A1 (0.47) | TAAR1 | |
| SCHEMBL24041839 | 0.80 | TDP1 (0.41) | TAAR1MAOB | |
| SCHEMBL11474319 | 0.80 | TAAR1 (0.39) | TAAR1MAOB | |
| SCHEMBL7866230 | 0.80 | CYP4F2 (0.47) | TAAR1 | |
| SCHEMBL7866228 | 0.80 | FFAR1 (0.40) | TAAR1MAOB | |
| SCHEMBL3589633 | 0.80 | NQO1 (0.50) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986264-A | Benzo nitrogen-containing polycyclic derivative regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-115583942-A | 2-substituted 5-phenyl-oxazole derivative, preparation method thereof and application thereof as MNK (MNK) inhibitor | 中国海洋大学 | 2023-01-10 | — | — | CN | disclosed |
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | TSUMURA & CO. (JP) | 2005-08-25 | — | — | US | disclosed |
| CN-1655783-A | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | TSUMURA & CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1495757-A1 | PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE | TSUMURA & CO. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6313153-B1 | ADMINISTERING PYRIDYLACRYLAMIDE COMPOUND FOR THERAPY OF NEPHRITIS | TSUMURA & CO. (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1000935-A1 | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | PDE3B, PDE3A, PDE2A | TAAR1 627/4885MAOB 142/4885CYP1A2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.